Validation of nomogram-based prediction of survival probability after salvage re-irradiation of head and neck cancer

Japanese Journal of Clinical Oncology

Volumn 43, Issue 2, 2013, Pages 154-160

  Shikama, Naoto ^a   Kumazaki, Yu ^a   Tsukamoto, Nobuhiro ^b   Ebara, Takeshi ^a   Makino, Soichi ^a   Abe, Takanori ^a   Nakahira, Mitsuhiko ^a   Sugasawa, Masashi ^a   Kato, Shingo ^a  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

Author keywords

Head and neck cancer; Nomogram; Salvage re irradiation; Stereotactic body radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; DISTANT METASTASIS; EAR CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEAD AND NECK CANCER; HUMAN; LYMPH NODE METASTASIS; MALE; NASOPHARYNX CANCER; NOMOGRAM; ORAL BLEEDING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SALVAGE THERAPY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL PREDICTION; TISSUE NECROSIS; TUMOR BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROBABILITY; RADIOSURGERY; REPRODUCIBILITY OF RESULTS; RETREATMENT; RISK ASSESSMENT; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84873429316     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys210     Document Type: Article

References (19)

1. Vargo JA, Wegner RE, Heron DE, et al. Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. Head Neck 2011;34:1153-61.
2. Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009;75:1493-500.
3. McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011;80:1292-8.
4. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:731-40.
5. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245- 51.
6. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007;25:4800-5.
7. Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001;51:1299-304.
8. Chen AM, Phillips TL, Lee NY. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? Int J Radiat Oncol Biol Phys 2011;81:1211-9.
9. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008;26:5518-23.
10. Popovtzer A, Gluck I, Chepeha DB, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 2009;74:1342-7.
11. Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009;73:399-409.
12. Haraf DJ, Weichselbaum RR, Vokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol 1996;7:913-8.
13. Tanvetyanon T, Padhya T, McCaffrey J, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009;27:1983-91.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
15. Hoebers F, Heemsbergen W, Moor S, et al. Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys 2011;81:e111-8.
16. Kramer NM, Horwitz EM, Cheng J, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 2005;27:406-14.
17. Spencer S, Wheeler R, Peters G, et al. Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck 2003;25:118-22.
18. McDonald MW, Moore MG, Johnstone PA. Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys 2012;82:1083-9.
19. Unger KR, Lominska CE, Deeken JF, et al. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010;77:1411-9.